Evidence mapPaperPMID 33929276Full record

SynthesisExpert review of anti-infective therapy2021

Brian Shing, Mina Balen, James H McKerrow, Anjan Debnath

Abstract readSystematic Review
In one paragraph

Synthesis in Expert review of anti-infective therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Acanthamoeba keratitis: from pathophysiology to prevention, a contemporary clinical perspective.Medical hypothesis, discovery & innovation ophthalmology journal · 2025
    Review
  10. Review
  11. Article
  12. Article
  13. Anti-Acanthamoeba metallopharmaceuticals: Amoebicidal activity and synergistic effect of copper(II) coordination compound.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2024
    Article
  14. Article
  15. Article
  16. Review
  17. Amoebicidal Effect of COVID Box Molecules againstPharmaceuticals (Basel, Switzerland) · 2024
    Article
  18. Article
  19. Novel anti-Frontiers in cellular and infection microbiology · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Brian ShingBiomedical Sciences Graduate Division, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-5579-8940
Mina BalenCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.
James H McKerrowCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.
Anjan DebnathCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0001-9294-3927

Funding

NIAID NIH HHS R21 AI146460
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AcanthamoebaAcanthamoeba KeratitisAmebicidesAzolesDrug Evaluation, PreclinicalHumansAmebicidesAzolesAcanthamoebaamebicidalantifungalassayazolecell viabilitycysticidaldrugsdrug screeningkeratitis treatments

Identifiers

PMID33929276
PMCPMC8551003

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.